We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effect of Hemodialysis on Efficacy and Pharmacokinetics of Sofosbuvir Coformulated with Either Daclatasvir or Ledipasvir in Patients with End-Stage Renal Disease.
- Authors
Lin, Ting; Wang, Xipei; Gao, Hongbo; Feng, Zhonglin; Xu, Lixia; Ma, Jianchao; Li, Zhuo; Zhang, Li; Huang, Renwei; Liang, Xinling; Liu, Shuangxin
- Abstract
Background/Aims: Direct-acting antivirals (DAAs) play a key role in the eradication of hepatitis C virus (HCV) infection. However, limited data are available on DAA for treating HCV infection in hemodialysis (HD) patients. This study was to evaluate the pharmacokinetic characteristics and effectiveness of daclatasvir/sofosbuvir (DAC/SOF) and ledipasvir/SOF (LDV/SOF) in HD patients. Methods: Seven patients were given SOF coadministered with DAC or LDV once daily for 12 weeks. The plasma concentrations of SOF007, DAC, and LDV were determined by high-performance liquid chromatography-electrospray ionization tandem mass spectrometry. Results: A sustained virologic response in week 12 (SVR12) was achieved in 6 (100%) patients, except for 1 patient dying due to severe cerebral hemorrhage not related to antiviral therapy. The extraction ratio of SOF007 was 66.67%, and the estimated HD clearance of SOF007 was 5.65 L/h. Conclusion: The combination of SOF with either DAC or LDV is well tolerated and offers high SVR12 in HD patients.
- Subjects
CHRONIC kidney failure; TANDEM mass spectrometry; SOFOSBUVIR; HEPATITIS C virus; PHARMACOKINETICS
- Publication
Blood Purification, 2020, Vol 49, Issue 6, p692
- ISSN
0253-5068
- Publication type
Article
- DOI
10.1159/000499161